- Remunity™ (treprostinil)
-
Product
Remunity™
(treprostinil)Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Please click here to see important safety information
Status
Devices / Commercially launched U.S. sales Feb 2021 - Implantable System for Remodulin® (treprostinil)
-
Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Please click here to see important safety information
Status
Devices / FDA Approved*Implantable System for intravenous delivery of Remodulin® (treprostinil).
*FDA requires that certain conditions of Medtronic’s PMA approval of the Implantable System for Remodulin must be satisfied prior to launch or sale of the Implantable System for Remodulin; accordingly, Implantable System for Remodulin labeling may be revised in the process of satisfying such conditions of approval.
LEARN MORE Close - Trevyent® (treprostinil sodium)
-
Product
Trevyent®
(treprostinil sodium)Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Devices / Preparing NDA ResubmissionPrefilled, pre-programmed, single-use PatchPump® for subcutaneous administration of treprostinil.
LEARN MORE Close - RemoLife (treprostinil)
-
Product
RemoLife
(treprostinil)Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Devices / Prototype development - RemoPro™ (treprostinil prodrug)
-
Product
RemoPro™
(treprostinil prodrug)Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Phase 1Prodrug of treprostinil that is being developed to reduce site pain associated with subcutaneous delivery of treprostinil.
LEARN MORE Close
Menu